K-numberK242089
Device nameVitrification Freeze Kit (RFD-0101) Vitrification Thaw Kit (RFD-0201, RFD-0202)
ApplicantJiangsu Ruifuda Medical Device Co., Ltd.
Product codeMQL
Device classClass II
Decision dateApr 10, 2025
DecisionSubstantially Equivalent
Regulation884.6180
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Vitrification Freeze Kit (RFD-0101) and Vitrification Thaw Kit (RFD-0201, RFD-0202) are reproductive media used in assisted reproduction to freeze and thaw oocytes, zygotes, cleavage-stage embryos, and blastocysts. The Freeze Kit contains an Equilibration Solution and Vitrification Solution with cryoprotectants; the Thaw Kit contains four sequential thawing solutions to safely restore vitrified embryos.

Technological characteristics

Both subject and predicate use aseptic filtration sterilization and achieve sterility with <0.5 EU/mL endotoxin. Key differences include: subject device pH range 7.30–7.70 vs. predicate 7.20–7.40; subject osmolality lower (ES 700±70, VS 1000±80 vs. predicate 2331–6849 mOsm/kg); subject shelf-life 7 weeks vs. predicate 52 weeks; and formulation differences (subject uses Quinn's Advantage Medium; predicate uses Modified Human Tubal Fluid with amino acids). Both meet ≥80% embryo development to blastocyst at 96 hours.

Test standards cited

ISO 13408-1:2008 (Aseptic Processing Part 1), ISO 13408-2:2018 (Aseptic Processing Part 2 Sterilizing Filtration), USP <791> (pH), USP <785> (Osmolality), USP <85> (Endotoxin), USP <71> (Sterility), Mouse Embryo Assay (MEA), ASTM D4169-22 (Transportation testing), and USP <1207.2> (Shipping).

Substantial equivalence argument

The subject device has identical indications for use and conditions of use (prescription-only, embryo vitrification and thawing) as the predicate SAGE kits. Although formulation and several parameters differ—pH range, osmolality, shelf-life, and base media composition—the applicant argues these differences do not raise new safety or effectiveness questions because both devices meet the same functional performance endpoint (≥80% blastocyst development). Both use the same sterilization method (aseptic filtration), achieve equivalent sterility and endotoxin levels, and undergo shelf-life and transportation testing. The lower osmolality and shorter shelf-life of the subject device represent conservative specifications rather than reduced safety margins.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →